Bioactivity | Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC50s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines[1]. |
Target | IC50: 1.8 μM (SIRT1), 2.4 μM (SIRT2), 65 μM (SIRT3) |
Invitro | Sirt1/2-IN-2 (compound hsa55) (5 μM; 48 h) 诱导不同肿瘤细胞凋亡,IC50 分别为 13 μM (MV4-11)、11.5 μM (MOLM-13)、34.4 μM (THP1)、27.5 μM (Jurkat)[1]。Sirt1/2-IN-2 (100 μM; 30 min) 会降低 SIRT1 和 SIRT2 蛋白在不同温度下的热稳定性,并且 (25 μM、30 μM; 24 h) 会增加 MOLM-13 细胞中 p53 和 α 微管蛋白乙酰化形式的水平[1]。 0 --> Sirt1/2-IN-2 相关抗体: |
Name | Sirt1/2-IN-2 |
CAS | 670267-73-9 |
Formula | C18H14N4O3S2 |
Molar Mass | 398.46 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Cai H, et al. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells. J Chem Inf Model. 2023 Aug 14;63(15):4780-4790. |